France's SpineGuard H1 revenue falls 32% on US business model shift

Spineguard SA

08/07/2026 17:09

Overview
France medical device maker's H1 2026 revenue fell 32% yr/yr to €1.45 mln
Revenue decline mainly due to U.S. shift from direct sales to distribution model
European sales grew, while company aims for operational breakeven by end-2026

Outlook
SpineGuard aims to reach operating breakeven in Q4 2026
Company expects gradual ramp-up in U.S. sales volumes via Omnia Medical partnership
SpineGuard believes its financing needs are covered through Q2 2027

Result Drivers
U.S. BUSINESS MODEL SHIFT - Co attributed revenue and unit sales decline to transition from direct sales to distribution model, leading to short-term inventory build-up and pricing effects
EUROPEAN SALES GROWTH - Co said Europe region grew 17% in H1, driven by established distributors and new commercial agreements
NEW MARKETS ORDERS - Co reported initial orders from China and Saudi Arabia, with further orders expected in coming months

Company press release: ID:nBw1mkFWQa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Sales
 
EUR 1.45 mln
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Spineguard SA is €0.43, about 405.3% above its July 7 closing price of €0.09

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)